NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) – Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced plans to present analyses from its open-label safety switching study (Study 303) assessing the effects of long-term administration of lumateperone in patients with stable symptoms of schizophrenia at the upcoming 2019 Congress of the Schizophrenia International Research Society being held in Orlando, FloridaApril 10-14, 2019.
Poster #S117 entitled “Favorable Long-Term Safety Profile of Lumateperone (ITI-007): Results from a 12-Month Open Label Safety Study in Patients with Stable Symptoms of Schizophrenia” will be presented on Saturday April 13th12:00-2:00 pm ET during Poster Session III.